The data are strongly positive and derisk the first-line label expansion. Monitor for sNDA acceptance and FDA priority review status in Q4 2026. The WCLC Presidential Symposium presentation adds peer-reviewed credibility. GSK's oncology pipeline value is incrementally re-rated upward.
Drug in focus
GSK drug pipeline →Jideytro
● Neutral Named in this 6-K- Impact
- Phase
- Approved (FDA); supported by the ARROS-1 phase I/II pivotal trial
- Time to market
- Approved and on the market in the US (approval 2026-07-22); additional global/regulatory filings and a first-line label expansion pending
- Next catalyst
- None dated
What to watchFor GSK shareholders this is a strategic-validation story, not a share-price catalyst: the approval news is out, and GSK's three most recent FDA approvals (Lynavoy, Exdensur, Blenrep) were each followed by slightly negative one-day moves (avg -2.19%), consistent with a mega-cap where single drugs barely move the tape. Watch the planned 2H-2026 first-line sNDA submission and commercial uptake of Jideytro, plus sister asset neladalkib (ALK inhibitor) with its own PDUFA later in 2026, the bigger single-stock binary for the Nuvalent deal thesis.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $50.05entry
- T+1 · 2mo ago −0.08%α +0.38% · $50.01
- T+5 · 8w ago +2.06%α +1.95% · $51.08
- T+20 · 5w ago −6.25%α −8.52% · $46.92
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1-positive NSCLC, showing a 94% objective response rate and 90% 12-month progression-free survival. The results support a planned supplemental NDA to the FDA in 2026 to expand the indication from second-line to first-line treatment, which could meaningfully expand the drug's addressable market and peak sales potential.
Key Facts
- 94% objective response rate (ORR) in 94 TKI-naïve patients at 15.2 months median follow-up
- 90% of patients progression-free at 12 months; median PFS not yet reached
- 70% of patients with measurable brain metastases achieved complete intracranial clearance
- Only 1% treatment discontinuation rate due to TRAEs; 11% dose reduction rate
- US regulatory submission (sNDA) for first-line indication planned in 2026
- Drug already FDA-approved for second-line ROS1-positive NSCLC (July 2026)
- Asset acquired via Nuvalent acquisition completed July 2026
Financial Impact
Expanding Jideytro to first-line ROS1-positive NSCLC could address an estimated ~50,000 new annual diagnoses worldwide (2% of NSCLC). First-line label typically captures 2-3x the peak sales of second-line only. No specific revenue figures provided in filing.
Risk Factors
- Regulatory risk: FDA may require additional data or raise concerns about single-arm trial design for first-line approval
- Competitive risk: existing ROS1 TKIs (entrectinib, repotrectinib, taletrectinib) may have overlapping profiles
- Commercial execution risk: GSK must build NSCLC commercial infrastructure against established players
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008318 |
| Document: 0001654954-26-008318-index-headers.html | 0001654954-26-008318 |
| Document: 0001654954-26-008318-index.html | 0001654954-26-008318 |
| Document: 0001654954-26-008318.txt | 0001654954-26-008318 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers